Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.024 EUR | +0.59% | -4.66% | -20.50% |
14/03 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
11/03 | Abionyx: reduced net loss in 2023 | CF |
Sales 2023 | 4.6M 4.92M 410M | Sales 2024 * | 4.6M 4.92M 410M | Capitalization | 32.98M 35.26M 2.94B |
---|---|---|---|---|---|
Net income 2023 | -3M -3.21M -268M | Net income 2024 * | -6M -6.42M -535M | EV / Sales 2023 | 9.02 x |
Net cash position 2023 * | 100K 107K 8.92M | Net cash position 2024 * | 3.4M 3.64M 303M | EV / Sales 2024 * | 6.43 x |
P/E ratio 2023 * |
-7.31
x | P/E ratio 2024 * |
-6.83
x | Employees | 63 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.63% |
1 day | +0.59% | ||
1 week | -4.66% | ||
Current month | +4.49% | ||
1 month | +10.11% | ||
3 months | -18.08% | ||
6 months | -20.00% | ||
Current year | -20.50% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 01/07/01 |
Director of Finance/CFO | - | 01/08/01 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 09/15/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 06/15/06 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 01/07/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.024 | +0.59% | 25,009 |
25/24/25 | 1.018 | -2.12% | 21,326 |
24/24/24 | 1.04 | -1.52% | 22,531 |
23/24/23 | 1.056 | +0.57% | 21,214 |
22/24/22 | 1.05 | -2.23% | 20,382 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.50% | 35.21M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ABNX Stock